March 30, 2022
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 Million Financing Round and on Track to Exit COVID-19 Business - Management to Host Conference Call at 2 p.m.
February 22, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’s
February 1, 2022
Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven
January 20, 2022
CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AI NPC is a rare genetic disease occurring in approximately 1 in 120,000 live births, with many cases going mis- or undiagnosed There are currently no
Displaying 11 - 20 of 21